<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Oppenheimer Touts Boston Scientific Corporation (BSX) as the Best Large-Cap MedTech — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Oppenheimer Touts Boston Scientific Corporation (BSX) as the Best Large-Cap MedTech</h2>
    <div class="badge">2025-09-15T13:03:30+00:00</div>
    <ul>
      <li>Its competitive edge was the catalyst behind a 17% organic revenue growth in the second quarter of 2025 as earnings per share increased 23%.</li>
<li>The company has delivered a strong performance, with 21.44% revenue growth over the past 12 months.</li>
<li>In addition, the research firm has echoed the company’s projected 11%-13% compound annual growth rate outlook.</li>
<li>On September 8, analysts at Oppenheimer upgraded the stock to an ‘Outperform’ from Perform and reiterated a $125 price target.</li>
<li>READ NEXT: 11 Best Wind Power and Solar Stocks to Buy According to Analysts and 10 Best Robinhood Penny Stocks to Invest In.</li>
<li>Disclosure: None.</li>
<li>This article is originally published at Insider Monkey.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Oppenheimer%20Touts%20Boston%20Scientific%20Corporation%20%28BSX%29%20as%20the%20Best%20Large-Cap%20MedTech%0A%E2%80%A2%20Its%20competitive%20edge%20was%20the%20catalyst%20behind%20a%2017%25%20organic%20revenue%20growth%20in%20the%20second%20quarter%20of%202025%20as%20earnings%20per%20share%20increased%2023%25.%0A%E2%80%A2%20The%20company%20has%20delivered%20a%20strong%20performance%2C%20with%2021.44%25%20revenue%20growth%20over%20the%20past%2012%20months.%0A%E2%80%A2%20In%20addition%2C%20the%20research%20firm%20has%20echoed%20the%20company%E2%80%99s%20projected%2011%25-13%25%20compound%20annual%20growth%20rate%20outlook.%0A%E2%80%A2%20On%20September%208%2C%20analysts%20at%20Oppenheimer%20upgraded%20the%20stock%20to%20an%20%E2%80%98Outperform%E2%80%99%20from%20Perform%20and%20reiterated%20a%20%24125%20price%20target.%0A%E2%80%A2%20READ%20NEXT%3A%2011%20Best%20Wind%20Power%20and%20Solar%20Stocks%20to%20Buy%20According%20to%20Analysts%20and%2010%20Best%20Robinhood%20Penny%20Stocks%20to%20Invest%20In.%0A%E2%80%A2%20Disclosure%3A%20None.%0A%E2%80%A2%20This%20article%20is%20originally%20published%20at%20Insider%20Monkey.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Foppenheimer-touts-boston-scientific-corporation-bsx-as-the-best-large-cap-medtec%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/oppenheimer-touts-boston-scientific-corporation-130330776.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>